Core Viewpoint - China's leading telecommunication firms, Huawei and ZTE, have secured multiple contracts this year to supply 5G equipment in Vietnam, indicating a strengthening relationship between Hanoi and Beijing, which raises concerns among Western officials [1] Group 1 - Huawei and ZTE are the primary companies involved in the 5G equipment supply contracts in Vietnam [1] - The contracts signify a deepening of ties between Vietnam and China, reflecting geopolitical shifts in the region [1] - The involvement of these Chinese firms has raised alarms among Western officials regarding security and influence in Southeast Asia [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Delray Beach, FL, Nov. 27, 2025 (GLOBE NEWSWIRE) -- According to a research report published by MarketsandMarkets, the global food packaging market is entering a new era. Valued at USD 421.38 billion in 2025, the industry is set to climb to USD 548.51 billion by 2030, powered by a 5.4% CAGR. Behind this surge is a blend of shifting consumer habits, sustainability demands, and rapid packaging innovation - all reshaping how food is protected, preserved, and delivered. From dairy to fresh produce, sauces to re ...

Core Viewpoint - Eisai Co., Ltd. and Biogen Inc. have filed a new drug application for a subcutaneous formulation of LEQEMBI (lecanemab) in Japan, aiming to provide an alternative administration route for Alzheimer's disease treatment [1][2][3] Group 1: Drug Application and Administration - The application is based on Phase 3 Clarity AD open-label extension data, confirming that a once-weekly subcutaneous administration of 500 mg is equivalent to the current intravenous administration every two weeks [2] - If approved, the subcutaneous autoinjector (SC-AI) would allow patients to administer LEQEMBI at home, potentially reducing healthcare resource utilization associated with intravenous dosing [3] Group 2: Clinical Efficacy and Safety - LEQEMBI targets both protofibrils and amyloid plaques, addressing the neurotoxic processes in Alzheimer's disease, and has shown a safety profile similar to intravenous administration with less than 2% incidence of systemic reactions [2][4] - The drug is currently approved in 51 countries and regions and is under regulatory review in 9 countries, indicating a broad acceptance and ongoing evaluation of its efficacy [4][9] Group 3: Collaboration and Development - Eisai leads the global development and regulatory submissions for lecanemab, with Biogen co-commercializing and co-promoting the product [5][11] - The collaboration between Eisai and BioArctic has been ongoing since 2005, focusing on the development and commercialization of Alzheimer's disease treatments [12]

Group 1 - The meeting is being opened by Dame Joan Withers, the Chair of The Warehouse Group, following a brief introduction by Silvana Roest, the Chief Legal and Corporate Affairs Officer [1][3] - Silvana Roest provided housekeeping details, including emergency procedures and location of facilities [2] - Attendees are informed about the availability of voting forms and are invited to refreshments after the meeting [3]

Core Viewpoint - Rosen Law Firm is urging investors of DexCom, Inc. to take action before the December 29, 2025 deadline for a securities class action related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the lead plaintiff deadline of December 29, 2025, and can do so by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].

ROSEN, A LEADING AND RANKED FIRM, Encourages Inspire Medical Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INSPNovember 27, 2025 7:03 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 27, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Per ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive athleisure market. Will it be a market beater or a missed opportunity?Explore the exciting world of Lululemon (LULU +2.50%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of Oct. 15, 2025. The video was published ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Axalta Coating Systems Ltd. (NYSE: AXTA)’s sale to Akzo Nobel N.V. for 0.6539 shares of AkzoNobel stock for each share of Axalta common stock. If you are an Axalta shareholder, click here to learn more about your rights and options. Semrush Holdings, Inc. (NY ...